Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Company profile
Ticker
ALGS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Aligos Belgium BV • Aligos Australia Pty LTD • Aligos Therapeutics (Shanghai) Co. Ltd. ...
ALGS stock data
Analyst ratings and price targets
Current price
Average target
$5.00
Low target
$3.00
High target
$7.00
Piper Sandler
Maintains
$7.00
Jefferies
Upgraded
$3.00
Latest filings (excl ownership)
UPLOAD
Letter from SEC
27 Dec 22
CORRESP
Correspondence with SEC
22 Dec 22
UPLOAD
Letter from SEC
8 Dec 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
2 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4 May 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 86.52 mm | 86.52 mm | 86.52 mm | 86.52 mm | 86.52 mm | 86.52 mm |
| Cash burn (monthly) | (no burn) | 12.82 mm | 6.32 mm | 9.40 mm | 5.71 mm | 8.34 mm |
| Cash used (since last report) | n/a | 53.57 mm | 26.39 mm | 39.29 mm | 23.86 mm | 34.84 mm |
| Cash remaining | n/a | 32.95 mm | 60.13 mm | 47.23 mm | 62.66 mm | 51.68 mm |
| Runway (months of cash) | n/a | 2.6 | 9.5 | 5.0 | 11.0 | 6.2 |
Institutional ownership, Q3 2022
85.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 53 |
| Opened positions | 3 |
| Closed positions | 14 |
| Increased positions | 12 |
| Reduced positions | 17 |
| 13F shares | Current |
|---|---|
| Total value | 225.85 mm |
| Total shares | 36.78 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| EcoR1 Capital | 3.95 mm | $4.34 mm |
| Vivo Capital VIII | 3.55 mm | $46.82 mm |
| Vivo Capital | 3.55 mm | $3.90 mm |
| Roche Finance | 3.09 mm | $85.50 mm |
| Hillhouse Capital Advisors | 2.37 mm | $2.60 mm |
| Versant Venture Management | 2.32 mm | $2.55 mm |
| Baker Bros. Advisors | 2.08 mm | $2.28 mm |
| Novo Holdings A/S | 1.95 mm | $2.15 mm |
| Tang Capital Management | 1.67 mm | $1.84 mm |
| Adage Capital Partners GP, L.L.C. | 1.47 mm | $1.62 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Jul 22 | Julian A. Symons | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 50,000 | 70.50 k | 50,000 |
| 7 Jul 22 | Lawrence Blatt | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 161,700 | 228.00 k | 161,700 |
| 7 Jul 22 | Lesley Ann Calhoun | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 52,500 | 74.03 k | 52,500 |
| 7 Jul 22 | Leonid Beigelman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 113,000 | 159.33 k | 113,000 |
| 7 Jul 22 | Matthew W. McClure | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 46,000 | 64.86 k | 46,000 |
News
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
17 Jan 23
Piper Sandler Maintains Overweight on Aligos Therapeutics, Raises Price Target to $7
17 Jan 23
12 Health Care Stocks Moving In Monday's After-Market Session
16 Jan 23
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
6 Jan 23
12 Health Care Stocks Moving In Friday's Intraday Session
6 Jan 23
Press releases
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
5 Jan 23
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
14 Dec 22
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
8 Dec 22